PanTher Secures Two Patents for Pancreatic Cancer Platform
The U.S. patents cover its Sagittari drug-delivery platform and PTM-101 lead candidate, and Tim Clackson has been named Executive Chair.
Updated on Nov. 13, 2026 in Cancer

PanTher Therapeutics has received two U.S. patents protecting its Sagittari platform and its pancreatic cancer lead product, PTM-101. The company also appointed Tim Clackson, Ph.D., as Executive Chair of its Board of Directors.
Why it matters
The patents extend protection for PanTher's approach of placing absorbable, multilayered implants directly on pancreatic tumors, a field where systemic chemotherapy is often limited by toxicity. The leadership appointment adds an executive with prior experience at IDRx, which GSK acquired for up to $1.15 billion.
U.S. Patent No. 12,605,356 covers methods of treating pancreatic tumors with multilayered, biodegradable implants, and U.S. Patent No. 12,508,222 covers drug-agnostic implants for local delivery. Clinical efficacy of PTM-101 has not yet been reported, and the Phase 1b study is only in its expansion phase.
The players
PanTher Therapeutics
A biotechnology company headquartered in Austin, Texas, with an office in Watertown, Massachusetts, developing localized drug-delivery implants for cancer.
Tim Clackson, Ph.D.
A biotechnology executive with more than 30 years of industry experience who previously served as CEO of IDRx.
The details
PTM-101 is an absorbable thin-film formulation of paclitaxel that is placed at the tumor surface during the standard staging laparoscopy patients already undergo at diagnosis. The Phase 1b study in non-metastatic pancreatic ductal adenocarcinoma has completed dose escalation and advanced into expansion.
Timeline
PanTher expects to share topline Phase 1b data in the first half of 2027.
Drs. Indolfi and Clackson will attend the Jefferies Global Healthcare Conference in London, November 16-19, 2026.
Industry Context
Clackson's prior role as CEO of IDRx, which GSK acquired for up to $1.15 billion, places PanTher's leadership change within a recent large-scale oncology acquisition. The new patents follow a pattern of companies protecting localized delivery methods for cancers where surgery remains the main curative option.
For patients with non-metastatic pancreatic cancer, PTM-101 is designed to deliver chemotherapy directly at the tumor during surgery staging rather than relying on systemic treatment. The approach remains investigational, and the Phase 1b study has not yet established clinical benefit.
The takeaway
Localized drug delivery for pancreatic cancer is still in early clinical testing, so readers should watch for topline Phase 1b results expected in 2027 before drawing conclusions about its effectiveness.
What happens next
PanTher expects to share topline data from the Phase 1b study of PTM-101 in the first half of 2027.
Further reading
For related coverage, explore Cancer news across the state.
Source note: This article includes information reported by Firstwordpharma.






